Hologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval
Zacks Investment Research | Oct 05, 2017 09:31PM ET
Hologic, Inc. (NASDAQ:HOLX) announced the receipt of 510(k) clearance from the FDA for Panther Fusion Flu A/B/RSV assay running on the new Panther Fusion system. Following its CE mark approval earlier this year, the latest FDA clearance can be treated as a major breakthrough for the company’s molecular diagnostics arm.
The Panther Fusion module is an in-lab upgrade to the original Panther instrument. This adds the flexibility of PCR (polymerase chain reaction) to the proven performance of transcription-mediated amplification (TMA), which is used by the Panther system. The Panther Fusion system has all the benefits of the Panther platform, including full sample-to-result automation, the ability to run multiple tests from a single sample, random access sample processing, continuous loading and STAT capabilities. Moreover, feature to provide higher throughput of up to 335 Panther Fusion tests in eight hours, or up to 500 Fusion and Aptima tests are also incorporated.
In the United States, the Panther Fusion is available as a full system, the testing capabilities of which can be extended by attaching the Panther Fusion module to existing Panther systems.
Apart from the Panther Fusion Flu A/B/RSV assay, two additional respiratory panels, the Panther Fusion Paraflu assay and the Panther Fusion AdV/hMPV/RV (adenovirus/human metapneumovirus/rhinovirus) assay are presently under FDA review. According to the company, these three Panther Fusion respiratory assays will offer a modular approach to testing via the ability to run one, two or all three assays from a single patient specimen. The Panther Fusion assays also use ready-to-use reagents offering up to 60-day on-board stability.
The Panther Fusion system cuts down hands-on time for laboratories as it provides random and continuous access with rapid turnaround time. The Panther Fusion system is the only instrument that combines TMA (transcription-mediated amplification), real-time TMA and real-time PCR with full sample-to-result automation.
Hologic is consistently trying to expand its Diagnostic segment. Notably, the segment generated 35.2% of the total revenue in the last reported third quarter despite facing year-over-year decline of 8.3%.
According to CISION, the molecular diagnostics market is projected to reach a worth of $10.12 billion, at a CAGR of 9.1% from 2016 to 2021. Considering the huge potential of the market, we believe the company’s latest development is quite strategic.
Over the past month, Hologichas underperformed the broaderZacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.